Applied Filters
Repurposed drugs: protections and incentives
Repurposing drugs has very clear benefits. It gives companies the opportunity to develop entirely new uses for existing drugs that they don’t have patent protection, and may allow innovator companies to protect a molecule or formulation even after initial patent protection has expired.
Lundbeck loses €150m pay-for-delay appeal
Lundbeck has lost an appeal to the Court of Justice of the European Union (CJEU) to waive €150 million ($176 million) in fines levied against itself and a group of five generics manufacturers over ‘pay-for-delay’ deals for its antidepressant generics.
Fed Circ to rehear $235m ‘skinny label’ case
The US Court of Appeals for the Federal Circuit has agreed to reconsider its precedential ruling against Teva Pharmaceuticals for producing a generic hypertension and heart failure treatment, according to a Bloomberg Law report.
Johnson & Johnson unit settles patent dispute over hypertension drug
In a win for Johnson & Johnson, its Actelion unit has settled an infringement lawsuit after generic drug maker Laurus conceded that a patent for a pulmonary hypertension drug was valid.
Lawyer opposes Allergan’s bid for interlocutory appeal in FCA suit
Allergan should not be permitted to immediately appeal against a recent ruling which requires it to face allegations that it monopolised the pricing of dementia drugs, according to a New York-based patent attorney.
MSD and Glenmark appeal pay-for-delay Zetia dispute
Pharmaceutical companies MSD and Glenmark have argued that the class certification of wholesale buyers of cholesterol drug Zetia should be reversed because the circumstances of the class members do not justify an award of class status.
Skinny-label ruling will ‘decimate’ Hatch-Waxman, Fed Circuit told
One of the architects of the Hatch-Waxman Act has urged judges to reverse a decision which he says nullifies a key provision of the generic drug legislation.
Lawyers warn of Irish Sea split over SPCs
The UK is facing a divergence in supplementary protection certificate regulations across the Irish Sea post-Brexit.
Judge rejects Allergan challenge to FCA suit
A California judge has allowed a patent attorney to proceed with his claims against Allergan which allege the pharmaceutical company fraudulently obtained patents to monopolise pricing.
Tris blocks Actavis’ ADHD generic
New Jersey-based Tris Pharma has won a ruling blocking Teva-owned Actavis from launching a generic version of attention deficit and hyperactivity disorder drug Quillivant XR.
